GSK (LON:GSK) Hits New 1-Year Low - Time to Sell?

GSK plc (LON:GSK - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as GBX 1,274.50 ($16.68) and last traded at GBX 1,284.88 ($16.81), with a volume of 167829328 shares trading hands. The stock had previously closed at GBX 1,340.50 ($17.54).

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a report on Friday, March 28th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($23.63).

GSK Stock Up 2.2 %

The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The company has a fifty day moving average price of GBX 1,452.52 and a 200 day moving average price of GBX 1,412.54. The company has a market cap of £53.65 billion, a PE ratio of 21.36, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In related news, insider Wendy Becker acquired 536 shares of the stock in a transaction on Thursday, March 20th. The stock was acquired at an average price of GBX 1,515 ($19.82) per share, for a total transaction of £8,120.40 ($10,624.62). Also, insider Emma Walmsley sold 38,459 shares of GSK stock in a transaction dated Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.55), for a total value of £545,348.62 ($713,526.91). Insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.